Abstract
c-Fos proto-oncoprotein is a short-lived transcription factor degraded by the proteasome in vivo. Its mutated forms expressed by the mouse osteosarcomatogenic retroviruses, FBJ-MSV and FBR-MSV, are stabilized two- and threefold, respectively. To elucidate the mechanisms underlying v-FosFBJ and v-FosFBR protein stabilization, we conducted a genetic analysis in which the half-lives and the sensitivities to various cell-permeable protease inhibitors of a variety of cellular and viral protein mutants were measured. Our data showed that the decreased degradation of v-FosFBJ and v-FosFBR is not simply explained by the deletion of a c-Fos destabilizing C-terminal domain. Rather, it involves a complex balance between opposing destabilizing and stabilizing mutations which are distinct and which include virally-introduced peptide motifs in both cases. The mutations in viral Fos proteins conferred both total insensitivity to proteasomal degradation and sensitivity to another proteolytic system not naturally operating on c-Fos, explaining the limited stabilization of the two proteins. This observation is consistent with the idea that FBR-MSV and FBJ-MSV expression machineries have evolved to ensure controlled protein levels. Importantly, our data illustrate that the degradation of unstable proteins does not necessarily involve the proteasome and provide support to the notion that highly related proteins can be broken down by different proteolytic systems in living cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abbott DW and Holt JT. . 1997a J. Biol. Chem. 272: 14005–14008.
Abbott DW and Holt JT. . 1997b J. Biol. Chem. 272: 32454–32462.
Ahmed NN, Franke TF, Bellacosa A, Datta K, Gonzalez-Portal ME, Taguchi T, Testa JR and Tsichlis PN. . 1993 Oncogene 8: 1957–1963.
Aniento F, Papavassiliou AG, Knecht E and Roche E. . 1996 FEBS Lett. 390: 47–52.
Boutin JA. . 1997 Cell Signal 9: 15–35.
Boyd SD, Tsai KY and Jacks T. . 2000 Nat. Cell. Biol. 2: 563–568.
Carillo S, Pariat M, Steff AM, Roux P, Etienne-Julan M, Lorca T and Piechaczyk M. . 1994 Oncogene 9: 1679–1689.
Ciechanover A, Orian A and Schwartz AL. . 2000 Bioessays 22: 442–451.
Curran T. . 1988 The Oncogene Handbook. Elsevier pp. 307–325.
Curran T, Miller AD, Zokas L and Verma IM. . 1984 Cell 36: 259–268.
Curran T, Peters G, Van Beveren C, Teich NM and Verma IM. . 1982 J. Virol. 44: 674–682.
Curran T and Verma IM. . 1984 Virology 135: 218–228.
DeMartino GN and Slaughter CA. . 1999 J. Biol. Chem. 274: 22123–22126.
Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L and Stein RL. . 1997 J. Biol. Chem. 272: 182–188.
Doherty FJ and Mayer RJ. . 1992 Intracellular Protein Degradation. Oxford: IRL Press.
Freedman DA and Levine AJ. . 1998 Mol. Cell. Biol. 18: 7288–7893.
Geier E, Pfeifer G, Wilm M, Lucchiari-Hartz M, Baumeister W, Eichmann K and Niedermann G. . 1999 Science 283: 978–981.
Hakak Y and Martin GS. . 1999 Curr. Biol. 9: 1039–1042.
Hanahan D and Weinberg RA. . 2000 Cell 100: 57–70.
Harlow E and Lane D. . 1999 Using Antibodies: a Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA.
Harris KF, Shoji I, Cooper EM, Kumar S, Oda H and Howley PM. . 1999 Proc. Natl. Acad. Sci. USA 96: 13738–13743.
He H, Qi XM, Grossmann J and Distelhorst CW. . 1998 J. Biol. Chem. 273: 25015–25019.
Hermida-Matsumoto ML, Chock PB, Curran T and Yang DC. . 1996 J. Biol. Chem. 271: 4930–4936.
Hirai S, Kawasaki H, Yaniv M and Suzuki K. . 1991 FEBS Lett. 287: 57–61.
Jotte RM and Holt JT. . 1996 J. Cell. Biol. 135: 457–467.
Jotte RM, Kamata N and Holt JT. . 1994 J. Biol. Chem. 269: 16383–16396.
Kamata N and Holt JT. . 1992 Mol. Cell. Biol. 12: 876–882.
Kamata N, Jotte RM and Holt JT. . 1991 Mol. Cell. Biol. 11: 765–772.
Matsuda S, Suzuki-Fujimoto T, Minowa A, Ueno H, Katamura K and Koyasu S. . 1999 J. Biol. Chem. 274: 34515–34518.
Miao GG and Curran T. . 1994 Mol. Cell. Biol. 14: 4295–4310.
Olson EN, Towler DA and Glaser L. . 1985 J. Biol. Chem. 260: 3784–3790.
Osmulski PA and Gaczynska M. . 1998 Curr. Biol. 8: 1023–1026.
Palombella VJ, Rando OJ, Goldberg AL and Maniatis T. . 1994 Cell 78: 773–785.
Piechaczyk M and Blanchard JM. . 1994 Crit. Rev. Oncol. Hematol. 17: 93–131.
Resh MD. . 1994 Cell 76: 411–413.
Roux P, Blanchard JM, Fernandez A, Lamb N, Jeanteur P and Piechaczyk M. . 1990 Cell 63: 341–351.
Ruther U, Garber C, Komitowski D, Muller R and Wagner EF. . 1987 Nature 325: 412–416.
Ruther U, Komitowski D, Schubert FR and Wagner EF. . 1989 Oncogene 4: 861–865.
Salvat C, Acquaviva C, Scheffner M, Robbins I, Piechaczyk M and Jariel-Encontre I. . 2000 Eur. J. Biochem. 267: 3712–3722.
Salvat C, Aquaviva C, Jariel-Encontre I, Ferrara P, Pariat M, Steff AM, Carillo S and Piechaczyk M. . 1999 Mol. Biol. Rep. 26: 45–51.
Salvat C, Jariel-Encontre I, Acquaviva C, Omura S and Piechaczyk M. . 1998 Oncogene 17: 327–337.
Sambrook J, Fritsch EF and Maniatis T. . 1989 Molecular Cloning. Cold Spring Harbor Laboratory Press.
Schmidt J, Krump-Konvalinkova V, Luz A, Goralczyk R, Snell G, Wendel S, Dorn S, Pedersen L, Strauss PG and Erfle V. . 1995 Virology 206: 85–92.
Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM and Clurman BE. . 2000 Mol. Cell 5: 403–410.
Stancovski I, Gonen H, Orian A, Schwartz AL and Ciechanover A. . 1995 Mol. Cell. Biol. 15: 7106–7116.
Steff AM, Carillo S, Pariat M and Piechaczyk M. . 1997 Biochem. J. 323: 685–692.
Tao W and Levine AJ. . 1999 Proc. Natl. Acad. Sci. USA 96: 6937–6941.
Treier M, Staszewski LM and Bohmann D. . 1994 Cell 78: 787–798.
Tsurumi C, Ishida N, Tamura T, Kakizuka A, Nishida E, Okumura E, Kishimoto T, Inagaki M, Okazaki K, Sagata N, Ichihara A and Tanaka K. . 1995 Mol. Cell. Biol. 15: 5682–5687.
Van Beveren C, van Straaten F, Curran T, Muller R and Verma IM. . 1983 Cell 32: 1241–1255.
Verma R and Deshaies RJ. . 2000 Cell 101: 341–344.
Villa P, Kaufmann SH and Earnshaw WC. . 1997 Trends Biochem. Sci. 22: 388–393.
Watt F and Molloy PL. . 1993 Nucleic Acids Res. 21: 5092–5100.
Wilson T and Treisman R. . 1988 EMBO J. 7: 4193–4202.
Yonemoto W, McGlone ML and Taylor SS. . 1993 J. Biol. Chem. 268: 2348–2352.
Acknowledgements
This work was supported by grants from the CNRS, the Ligue contre le Cancer, the ARC and the ANRS. We are grateful to Drs O Coux, R Hipskind and N Taylor for critical reading of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Acquaviva, C., Salvat, C., Brockly, F. et al. Cellular and viral Fos proteins are degraded by different proteolytic systems. Oncogene 20, 942–950 (2001). https://doi.org/10.1038/sj.onc.1204155
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204155
Keywords
This article is cited by
-
N-Terminal c-Fos tyrosine phosphorylation regulates c-Fos/ER association and c-Fos-dependent phospholipid synthesis activation
Oncogene (2007)
-
Identification of a C-terminal tripeptide motif involved in the control of rapid proteasomal degradation of c-Fos proto-oncoprotein during the G0-to-S phase transition
Oncogene (2001)